

Evunzekibart Biosimilar - Research Grade

Product Code: ICH5236

More Information

Species Reactivity: Human

Target: TNFRSF9

Concentration: >1mg/ml

Isotype: Human IgG4 - kappa

Host: CHO Cells

product name H2: Evunzekibart Biosimilar - Research Grade

Antibodies against the same target: [Utomilumab Biosimilar - Research Grade \(ICH5014\)](#), [Urelumab Biosimilar - Research Grade \(ICH5015\)](#), [Exlinkibart Biosimilar - Research Grade \(ICH5541\)](#)

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: Q07011

Shipping Conditions: Blue ice

background: This product is an unconjugated, non-therapeutic recombinant analog of the originator antibody evunzekibart (ATOR-1017), supplied strictly for research use only. It is a human IgG4-kappa molecule built around the extracellular domain of 4-1BB (CD137, TNFRSF9), the same costimulatory receptor engaged by the originator, and it is manufactured as a functional research reagent rather than as the clinical drug. It is not intended for human or veterinary use. The material is produced at low endotoxin (research grade 1 EU/mg, with ultra-low 0.5 EU/mg options) and is available in bulk milligram-to-gram

quantities, making it well suited to work that consumes larger amounts of a defined, batch-consistent reagent. Typical research applications include use as a binding and specificity control, a benchmarking comparator for other anti-4-1BB agents, a positive control in receptor-engagement or reporter assays, a tool for studying 4-1BB agonism and Fc-gamma-receptor-dependent crosslinking, and as a starting point for conjugation, labeling, or ADCC/ADC development workflows. Its defined isotype and human framework make it a convenient reference antibody for in-vitro and preclinical characterization. 4-1BB (CD137), encoded by TNFRSF9 and mapping to UniProt Q07011, is a member of the tumor necrosis factor receptor superfamily and functions as an inducible costimulatory receptor. It is expressed primarily on activated CD4+ and CD8+ T cells, natural killer cells, regulatory T cells, and some myeloid and dendritic cell populations. Its natural ligand is 4-1BBL (TNFSF9), typically presented on activated antigen-presenting cells. Engagement and clustering of 4-1BB deliver a costimulatory signal, largely through TRAF1 and TRAF2 recruitment and downstream NF- κ B and MAPK activation, that enhances T-cell proliferation, cytokine production, survival, and effector and memory differentiation, and that boosts NK-cell cytotoxicity. Because agonist activity depends on receptor crosslinking, Fc-gamma-receptor engagement strongly influences signaling strength. These properties make 4-1BB a prominent target for cancer immunotherapy aimed at amplifying antitumor immune responses.

Other names: 4-1BB ligand receptor, CDw137, T-cell antigen 4-1BB homolog, T-cell antigen ILA, Tumor necrosis factor receptor superfamily member 9, CD137, ILA

Specificity: Detects human TNFRSF9

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.



Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 4 weeks